- Home
- ERAS vs PRTC Comparison
ERAS vs PRTC Comparison
Compare ERAS & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- PRTC
- Stock Information
- Founded
- ERAS 2018
- PRTC 2015
- Country
- ERAS United States
- PRTC United States
- Employees
- ERAS N/A
- PRTC N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- PRTC Biotechnology: Pharmaceutical Preparations
- Sector
- ERAS Health Care
- PRTC Health Care
- Exchange
- ERAS Nasdaq
- PRTC Nasdaq
- Market Cap
- ERAS 432.6M
- PRTC 431.1M
- IPO Year
- ERAS 2021
- PRTC N/A
- Fundamental
- Price
- ERAS $1.37
- PRTC $19.78
- Analyst Decision
- ERAS Strong Buy
- PRTC Buy
- Analyst Count
- ERAS 6
- PRTC 1
- Target Price
- ERAS $4.83
- PRTC $45.00
- AVG Volume (30 Days)
- ERAS 1.8M
- PRTC 2.1K
- Earning Date
- ERAS 03-20-2025
- PRTC 04-24-2025
- Dividend Yield
- ERAS N/A
- PRTC N/A
- EPS Growth
- ERAS N/A
- PRTC N/A
- EPS
- ERAS N/A
- PRTC N/A
- Revenue
- ERAS N/A
- PRTC $468,000.00
- Revenue This Year
- ERAS N/A
- PRTC N/A
- Revenue Next Year
- ERAS N/A
- PRTC $160.00
- P/E Ratio
- ERAS N/A
- PRTC N/A
- Revenue Growth
- ERAS N/A
- PRTC N/A
- 52 Week Low
- ERAS $1.23
- PRTC $16.30
- 52 Week High
- ERAS $3.45
- PRTC $34.00
- Technical
- Relative Strength Index (RSI)
- ERAS 39.36
- PRTC 65.61
- Support Level
- ERAS $1.40
- PRTC $16.30
- Resistance Level
- ERAS $1.61
- PRTC $18.34
- Average True Range (ATR)
- ERAS 0.11
- PRTC 0.43
- MACD
- ERAS 0.01
- PRTC 0.28
- Stochastic Oscillator
- ERAS 4.00
- PRTC 100.00
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About PRTC PureTech Health plc
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.